Cargando…

High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma

Detalles Bibliográficos
Autores principales:	Shan, Xinhe, Long, Qi, Garfall, Alfred L., Susanibar-Adaniya, Sandra P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203273/ https://www.ncbi.nlm.nih.gov/pubmed/37217520 http://dx.doi.org/10.1038/s41408-023-00855-1

Ejemplares similares

4473 Immune control of plasma cell disorders – in-depth analysis of Sox2 immunity in MGUS
por: Susanibar Adaniya, Sandra Patricia, et al.
Publicado: (2020)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
por: Yang, Peiyu, et al.
Publicado: (2022)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma
por: Leng, Siyang, et al.
Publicado: (2020)

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect(®) MM Registry
por: Lee, Hans C., et al.
Publicado: (2021)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
por: Saburi, Masuho, et al.
Publicado: (2020)

STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
por: D’Agostino, Mattia, et al.
Publicado: (2021)

Amplification of Chromosome 1q Predicts Poor Overall Survival in Newly Diagnosed Multiple Myeloma Patients
por: Skerget, Matevz, et al.
Publicado: (2023)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma
por: Ludwig, Heinz, et al.
Publicado: (2016)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Wang, Bei, et al.
Publicado: (2022)

Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients
por: Bao, Li, et al.
Publicado: (2020)

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
por: Gonsalves, W I, et al.
Publicado: (2015)

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
por: Chacon, Aurelia, et al.
Publicado: (2023)

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
por: Mina, Roberto, et al.
Publicado: (2021)

A novel E-cadherin/SOX9 axis regulates cancer stem cells in multiple myeloma by activating Akt and MAPK pathways
por: Samart, Parinya, et al.
Publicado: (2022)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients
por: Chen, Xuduan, et al.
Publicado: (2020)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
por: Sørrig, Rasmus, et al.
Publicado: (2017)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
por: Lopez-Muñoz, N., et al.
Publicado: (2023)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Smoldering Multiple Myeloma Arising in Ulcerative Colitis
por: Yang, Xue, et al.
Publicado: (2018)

Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
por: Bove, Virginia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mv7vr55v2nemn4sk0l6pk72l1i